Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.
The list of resources will be updated as new material becomes available so please check back regularly for updates.
The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice. In the absence of any COVID-specific advice then the usual Pan Mersey guidance and RAG rating will still apply unless otherwise indicated.
This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
The Pan Mersey Area Prescribing Committee recommends the prescribing of DAPOXETINE tablets (Priligy®) for the treatment of premature ejaculation when recommended by a psychosexual service or a specialist clinician with experience of treating psychosexual disorders. Treatment is restricted to three doses per month.
The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of PRASTERONE pessaries (Intrarosa®▼) for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.
The Pan Mersey Area Prescribing Committee recommends that TRIPTORELIN (Decapeptyl® SR 3mg, 11.25mg and 22.5mg) INTRAMUSCULAR INJECTION is first choice gonadorelin analogue for prostate cancer following specialist urologist / oncologist initiation under applicable local arrangement.
The Pan Mersey Area Prescribing Committee recommends the prescribing of ULIPRISTAL ACETATE tablets (Esmya®), by physicians experienced in the diagnosis and treatment of uterine fibroids, in line with the prescribing criteria defined.